Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

OPK-88004

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
OPK-88004
Legal status
Legal status
Identifiers
  • propan-2-ylN-[(2S)-7-cyano-4-(pyridin-2-ylmethyl)-2,3-dihydro-1H-cyclopenta[b]indol-2-yl]carbamate
CAS Number
PubChemCID
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC22H22N4O2
Molar mass374.444 g·mol−1
3D model (JSmol)
  • CC(C)OC(=O)N[C@H]1CC2=C(C1)N(C3=C2C=C(C=C3)C#N)CC4=CC=CC=N4
  • InChI=1S/C22H22N4O2/c1-14(2)28-22(27)25-17-10-19-18-9-15(12-23)6-7-20(18)26(21(19)11-17)13-16-5-3-4-8-24-16/h3-9,14,17H,10-11,13H2,1-2H3,(H,25,27)/t17-/m0/s1
  • Key:IHIWYQYVBNODSV-KRWDZBQOSA-N

OPK-88004 (formerly known asLY-2452473 orTT-701) is a non-steroidalindole derivative which acts as aselective androgen receptor modulator (SARM). It has been investigated byOPKO Health for the treatment oferectile dysfunction and symptoms associated withbenign prostate hyperplasia.[1][2][3]

Research

[edit]

The compound advanced to a phase II trial inbenign prostatic hyperplasia, but it was terminated due to difficulty in measuring prostate size, the trial's primary endpoint.[4]

It was also tried in a study to improve quality of life in patients withprostate cancer. Although it did not cause progression of the disease and increasedlean body mass, the drug did not improve sexual function.[3]

See also

[edit]

References

[edit]
  1. ^Yi P, Rehmel JF, Cassidy K, Hadden C, Campanale K, Patel N, Johnson J (December 2012). "Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans".Drug Metabolism and Disposition.40 (12):2354–2364.doi:10.1124/dmd.112.047613.PMID 22961682.S2CID 6942291.
  2. ^Noey EL, Yang Z, Li Y, Yu H, Richey RN, Merritt JM, et al. (June 2017). "Origins of Regioselectivity in the Fischer Indole Synthesis of a Selective Androgen Receptor Modulator".The Journal of Organic Chemistry.82 (11):5904–5909.doi:10.1021/acs.joc.7b00878.PMID 28467062.
  3. ^abPencina KM, Burnett AL, Storer TW, Guo W, Li Z, Kibel AS, et al. (July 2021)."A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial".The Journal of Clinical Endocrinology and Metabolism.106 (8):2171–2186.doi:10.1210/clinem/dgab361.PMC 8277210.PMID 34019661.
  4. ^Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW (March 2020)."Selective androgen receptor modulators: the future of androgen therapy?".Translational Andrology and Urology.9 (Suppl 2):S135 –S148.doi:10.21037/tau.2019.11.02.PMC 7108998.PMID 32257854.
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
Stub icon

Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=OPK-88004&oldid=1256764152"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp